General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy

Abstract Background and Aim To validate a composite predictive model for hepatocellular carcinoma (HCC) development in patients with advanced liver fibrosis associated with chronic hepatitis C virus (HCV) who have received direct‐acting antiviral (DAA) therapy and achieved sustained virologic respon...

Full description

Bibliographic Details
Main Authors: Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Koji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hideki Fujii, Toru Ishii, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Shinichiro Nakamura, Namiki Izumi
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:JGH Open
Subjects:
advanced liver fibrosis
direct‐acting antiviral
general evaluation score
hepatitis C virus
hepatocellular carcinoma
sustained virologic response
Online Access:https://doi.org/10.1002/jgh3.12778

Internet

https://doi.org/10.1002/jgh3.12778

Similar Items